Inhibikase Therapeutics, Inc. (NASDAQ: IKT) has received Orphan Drug Designation from the U.S. Food and Drug Administration for its lead product candidate, IKT-001.
This designation is for the treatment of pulmonary arterial hypertension (PAH), a rare disease affecting fewer than 200,000 patients in the United States.
Stay ahead of biotech and pharmaceutical market-moving events with the CatalystPICR FDA Calendar.
Mark Iwicki, Chief Executive Officer of Inhibikase, commented, “The grant of Orphan Drug Designation for IKT-001 by FDA is another important milestone for Inhibikase and reflects the high unmet medical need among the approximately 50,000 people suffering from PAH in the United States.”
